Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price

Arvinas (NASDAQ:ARVN) had its price objective cut by Stifel Nicolaus from $63.00 to $51.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts have also recently issued reports about the company. BMO Capital Markets decreased their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. Oppenheimer decreased their price target on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. HC Wainwright reiterated a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Finally, Guggenheim reiterated a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $60.00.

Arvinas Stock Performance

Shares of Arvinas stock opened at $18.31 on Wednesday. Arvinas has a 52-week low of $16.61 and a 52-week high of $53.08. The stock’s 50-day simple moving average is $18.88 and its 200 day simple moving average is $23.22. The stock has a market capitalization of $1.26 billion, a P/E ratio of -3.92 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. During the same period in the prior year, the firm earned ($2.53) earnings per share. Equities research analysts forecast that Arvinas will post -3.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Arvinas

Large investors have recently modified their holdings of the stock. nVerses Capital LLC bought a new position in Arvinas in the 3rd quarter worth about $39,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after purchasing an additional 440 shares in the last quarter. KBC Group NV boosted its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP boosted its stake in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after purchasing an additional 1,798 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.